Navigation Links
Dehaier Medical Receives CE Mark Approval to Sell Sleep Diagnostic Devices and Air Compressors in Europe

BEIJING, Jan. 10, 2012 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products, today announced that it has received Conformite Europeenne (CE) certification for its sleep diagnostic devices and air compressors.


Dehaier's DHR-998 sleep diagnostic device collects data on patients' respiration flow, pulse, oximetry, thoracoabdominal breathing, snoring and body position. Dehaier's air compressors are key supplemental devices for medical ventilators. The CE mark recognizes that the two products meet European Union (EU) health and safety standards and are approved for sale in the 27 member states of the EU and in the four members of the European Free Trade Association (EFTA).

Mr. Ping Chen, Chairman and Chief Executive Officer of Dehaier Medical stated, "We are thrilled to obtain the CE marking, which validates the high quality and manufacturing standards of Dehaier's innovative medical products. This lays a strong foundation for us to offer our sleep diagnostic devices and air compressors in the EU markets. Moreover, we intend to leverage this approval to further expand our distribution network in the European Union as well as other markets that rely on the CE mark process."

"We already ship our air compressor products to the Czech Republic, Hungary, Kyrgyzstan, Pakistan, Ukraine, and the Philippines. Following the CE approval, we will continue to seek more distribution and OEM opportunities worldwide," said Ms. Rayna Dong, Director of Dehaier's International Marketing. "The CE marking strengthens our ability to cooperate with potential distributors from EU countries. In the near term, we look to establish a strong footprint in the European market, which presents an enormous potential for Dehaier's medical equipment and homecare products."

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier's technology is based on five patents and five software copyrights; additionally Dehaier has three pending patents, six pending software copyrights and proprietary technology. More information may be found at

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular statements about Dehaier's international growth plans and prospects(such as any plans to expand into European markets), future acceptance of its products in China and abroad, receipt of regulatory approvals for Dehaier's products, the impact of receipt of such approvals on business prospects and results of relationships with distributors. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Us

Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080

Dehaier Medical Systems Limited
Lisa Zhou
+86 10-5166-0080

SOURCE Dehaier Medical Systems Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dehaier Medical Systems Announces Closing of Initial Public Offering on NASDAQ
2. Dehaier Medical Systems Announces First Quarter Net Income Up 54%
3. Dehaier Medical Systems Announces New Exclusive China Distribution Agreement with Welch Allyn, Further Broadening Companys Product Lines
4. Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell
5. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
6. Dehaier Medical Systems Acquires Emergency Ventilator Series to Extend Product Line
7. Dehaier Medical Systems Q2 Revenue Up 46% to $4.83 Million; Net Income Up 59% to 1.14 Million; EPS 0.27
8. Dehaier Medical Systems Announces Engagement of RedChip Companies to Lead Public and Investor Relations
9. Dehaier Medical Shows New Products at 2010 China International Medical Equipment Fair
10. Dehaier Medical Wins $2 Million Distribution Bid for Rural Healthcare Construction Project
11. Dehaier Medical to Participate in MEDICA International Trade Fair
Post Your Comments:
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)... Dec. 1, 2015  Six months of adjunctive metformin therapy ... 1 diabetes, according to new research from T1D Exchange ... may have a beneficial effect on measures of obesity, including ... of the Journal of the American Medical Association , ... effect of metformin on overweight and obese adolescents with type ...
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015 ... of the company’s growing product line of food safety and seafood fraud prevention ... (Oncorhynchus nerka) – allow InstantLabs to offer fast, reliable species identification for the ...
(Date:12/1/2015)... York, NY (PRWEB) , ... December 01, 2015 ... ... of non-traumatic limb amputations in the United States. Podiatrists are well aware that ... to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... Center of Excellence (BHCOE) today announced that the organization has awarded Education and ... Francisco, with a Distinguished Award. The award celebrates exceptional special needs providers that ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Effective Post-Affiliation Integration ,” addresses a main “pain point” for merging or aligning ... results, once a deal is signed. This quick-read guidance suggests that failing ...
(Date:12/1/2015)... Beverly Hills, CA (PRWEB) , ... December 01, ... ... honored by Modern Luxury’s Angeleno Magazine as a Modern Man for 2015. ... luxury lifestyle publisher in the United States. Established in 1994, Modern Luxury includes ...
Breaking Medicine News(10 mins):